Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PPIA | P62937 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171506 | 0.85 | PPIA (0.50) | NPSR1RAB9AKDM4EPPIAALDH1A1 | |
| SCHEMBL14045184 | 0.84 | HPGD (0.49) | RAB9AALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL14045079 | 0.84 | CA1 (0.51) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL13667641 | 0.83 | RIPK1 (0.52) | RIPK1NPSR1RAB9AKDM4EPPIA | |
| SCHEMBL13607973 | 0.81 | ANO1 (0.51) | RIPK1NPSR1RAB9AKDM4EPPIA | |
| SCHEMBL13926143 | 0.81 | ALDH1A1 (0.56) | NPSR1RAB9APPIAALDH1A1SMN1; SMN2 | |
| SCHEMBL14045189 | 0.81 | CA1 (0.43) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL2605728 | 0.80 | MEN1 (0.57) | NPSR1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL14045187 | 0.79 | HTT (0.41) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL10172594 | 0.78 | ALDH1A1 (0.58) | RAB9AALDH1A1SMN1; SMN2HPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | RIPK1 217/4885NPSR1 4396/4885RAB9A 1119/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | RIPK1 217/4885NPSR1 4396/4885RAB9A 1119/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | RIPK1 614/4885NPSR1 1765/4885RAB9A 2424/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | RIPK1 528/4885NPSR1 3678/4885RAB9A 2326/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | RIPK1 614/4885NPSR1 1765/4885RAB9A 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.